Research Progress on the Therapeutic Effects of Nanoparticles Loaded with Drugs Against Atherosclerosis

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2023 May 13

PMID 37178241

Authors

Tianfeng Shi

Kunkun Liu

Yueyou Peng

Weibin Dai

Donglian Du

Xiaoqiong Li

Tingting Liu

Ningning Song

Yanfeng Meng

Affiliations

Soon will be listed here.

Abstract

Presently, there are many drugs for the treatment of atherosclerosis (AS), among which lipid-lowering, anti-inflammatory, and antiproliferative drugs have been the most studied. These drugs have been shown to have inhibitory effects on the development of AS. Nanoparticles are suitable for AS treatment research due to their fine-tunable and modifiable properties. Compared with drug monotherapy, experimental results have proven that the effects of nanoparticle-encapsulated drugs are significantly enhanced. In addition to nanoparticles containing a single drug, there have been many studies on collaborative drug treatment, collaborative physical treatment (ultrasound, near-infrared lasers, and external magnetic field), and the integration of diagnosis and treatment. This review provides an introduction to the therapeutic effects of nanoparticles loaded with drugs to treat AS and summarizes their advantages, including increased targeting ability, sustained drug release, improved bioavailability, reduced toxicity, and inhibition of plaque and vascular stenosis.

Citing Articles

The two coin sides of bacterial extracellular membrane nanovesicles: atherosclerosis trigger or remedy.

Lusta K, Churov A, Beloyartsev D, Golovyuk A, Lee A, Sukhorukov V Discov Nano. 2024; 19(1):179.

PMID: 39532781 PMC: 11557815. DOI: 10.1186/s11671-024-04149-8.

References

Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P . Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2019; 395(10226):795-808. PMC: 8006904. DOI: 10.1016/S0140-6736(19)32008-2. View

Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S . Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res. 2016; 118(4):535-46. DOI: 10.1161/CIRCRESAHA.115.307611. View

Poznyak A, Wu W, Melnichenko A, Wetzker R, Sukhorukov V, Markin A . Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis. Cells. 2020; 9(3). PMC: 7140394. DOI: 10.3390/cells9030584. View

Prilepskii A, Serov N, Kladko D, Vinogradov V . Nanoparticle-Based Approaches towards the Treatment of Atherosclerosis. Pharmaceutics. 2020; 12(11). PMC: 7694323. DOI: 10.3390/pharmaceutics12111056. View

Distasio N, Lehoux S, Khademhosseini A, Tabrizian M . The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research. Materials (Basel). 2018; 11(5). PMC: 5978131. DOI: 10.3390/ma11050754. View

Shen Y, Liang L, Zhang S, Huang D, Zhang J, Xu S . Organelle-targeting surface-enhanced Raman scattering (SERS) nanosensors for subcellular pH sensing. Nanoscale. 2017; 10(4):1622-1630. DOI: 10.1039/c7nr08636a. View

Leal B, Velasco B, Cambon A, Pardo A, Fernandez-Vega J, Arellano L . Combined Therapeutics for Atherosclerosis Treatment Using Polymeric Nanovectors. Pharmaceutics. 2022; 14(2). PMC: 8879452. DOI: 10.3390/pharmaceutics14020258. View

Wei B, Li Y, Ao M, Shao W, Wang K, Rong T . Ganglioside GM3-Functionalized Reconstituted High-Density Lipoprotein (GM3-rHDL) as a Novel Nanocarrier Enhances Antiatherosclerotic Efficacy of Statins in apoE C57BL/6 Mice. Pharmaceutics. 2022; 14(11). PMC: 9698139. DOI: 10.3390/pharmaceutics14112534. View

Sun Y, Chen L, Zhao S, Shi L, Li H, Tian W . Effects of nanoparticle-mediated delivery of pitavastatin on atherosclerotic plaques in ApoE-knockout mice and THP-1-derived macrophages. Exp Ther Med. 2020; 19(6):3787-3797. PMC: 7185072. DOI: 10.3892/etm.2020.8632. View

10.

Imanparast F, Faramarzi M, Vatannejad A, Paknejad M, Deiham B, Kobarfard F . mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs. Microvasc Res. 2017; 112:14-19. DOI: 10.1016/j.mvr.2017.02.002. View

11.

Pham L, Kim E, Ou W, Phung C, Nguyen T, Pham T . Targeting and clearance of senescent foamy macrophages and senescent endothelial cells by antibody-functionalized mesoporous silica nanoparticles for alleviating aorta atherosclerosis. Biomaterials. 2021; 269:120677. DOI: 10.1016/j.biomaterials.2021.120677. View

12.

Chen L, Wang C, Wu Y . Cholesterol (Blood lipid) lowering potential of Rosuvastatin chitosan nanoparticles for atherosclerosis: Preclinical study in rabbit model. Acta Biochim Pol. 2020; 67(4):495-499. DOI: 10.18388/abp.2020_5186. View

13.

Saraogi G, Tholiya S, Mishra Y, Mishra V, Albutti A, Nayak P . Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management. Gels. 2022; 8(2). PMC: 8871575. DOI: 10.3390/gels8020081. View

14.

Chen F, Chen J, Han C, Yang Z, Deng T, Zhao Y . Theranostics of atherosclerosis by the indole molecule-templated self-assembly of probucol nanoparticles. J Mater Chem B. 2021; 9(20):4134-4142. DOI: 10.1039/d1tb00432h. View

15.

Chen L, Yang J, Fu X, Huang W, Yu X, Leng F . A targeting mesoporous dopamine nanodrug platform with NIR responsiveness for atherosclerosis improvement. Biomater Adv. 2022; 136:212775. DOI: 10.1016/j.bioadv.2022.212775. View

16.

You S, Guo X, Xue X, Li Y, Dong H, Ji H . PCSK9 Hapten Multicopy Displayed onto Carrier Protein Nanoparticle: An Antiatherosclerosis Vaccine. ACS Biomater Sci Eng. 2021; 5(9):4263-4271. DOI: 10.1021/acsbiomaterials.9b00434. View

17.

Roberts W . The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997; 80(1):106-7. View

18.

Laufs U, Scharnagl H, Marz W . Statin intolerance. Curr Opin Lipidol. 2016; 26(6):492-501. DOI: 10.1097/MOL.0000000000000236. View

19.

Nenna A, Nappi F, Larobina D, Verghi E, Chello M, Ambrosio L . Polymers and Nanoparticles for Statin Delivery: Current Use and Future Perspectives in Cardiovascular Disease. Polymers (Basel). 2021; 13(5). PMC: 7956757. DOI: 10.3390/polym13050711. View

20.

Hagg D, Sjoberg S, Mattsson Hulten L, Fagerberg B, Wiklund O, Rosengren A . Augmented levels of CD44 in macrophages from atherosclerotic subjects: a possible IL-6-CD44 feedback loop?. Atherosclerosis. 2006; 190(2):291-7. DOI: 10.1016/j.atherosclerosis.2006.03.020. View